These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 6418412)

  • 1. Valproate-induced hyperammonemia in asymptomatic children.
    Wyllie E; Wyllie R; Rothner AD; Erenberg G; Cruse RP
    Cleve Clin Q; 1983; 50(3):275-7. PubMed ID: 6418412
    [No Abstract]   [Full Text] [Related]  

  • 2. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 3. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 5. Hyperaminoacidemia in epileptic children treated with valproic acid.
    Castro-Gago M; Rodrigo-Saez E; Novo-Rodriguez I; Camiña MF; Rodriguez-Segade S
    Childs Nerv Syst; 1990 Dec; 6(8):434-6. PubMed ID: 2095300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproate-induced hyperammonemia.
    Batshaw ML; Brusilow SW
    Ann Neurol; 1982 Mar; 11(3):319-21. PubMed ID: 6807193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Incidence of pathologic ammonia concentrations in the plasma in children with seizure disorders treated with Convulsofin/Convulex and other anticonvulsants in comparison with children with brain damage and healthy children].
    Wiedemann G; Haupt M; Rommel A; Rommel KF; Biesenbach R; Schmidt W
    Kinderarztl Prax; 1990 Jan; 58(1):21-7. PubMed ID: 2110274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate acute administration, EEG epileptic abnormalities, and ammonemia.
    Sannita WG
    Neurology; 1992 Oct; 42(10):2003-5. PubMed ID: 1407583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asymptomatic hyperammonemia in patients receiving valproic acid.
    Murphy JV; Marquardt K
    Arch Neurol; 1982 Sep; 39(9):591-2. PubMed ID: 6810855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of valproate on mitochondrial function in epileptic patients].
    Kanayama M; Sugiyama N; Morishita H; Ishikawa T; Wada Y; Akiyama T
    No To Hattatsu; 1985 Nov; 17(6):507-13. PubMed ID: 3936523
    [No Abstract]   [Full Text] [Related]  

  • 14. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hyperammonemia during sodium valproate therapy: clinically relevant or accidental finding?].
    Ettlin T; Scollo-Lavizzari G
    Schweiz Rundsch Med Prax; 1986 Jul; 75(29):881-5. PubMed ID: 3090672
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hyperammonemia in valproate therapy in children and adolescents].
    Laub MC
    Nervenarzt; 1986 May; 57(5):314-8. PubMed ID: 3088461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal handling of carnitine in children with carnitine deficiency and hyperammonemia associated with valproate therapy.
    Matsuda I; Ohtani Y; Ninomiya N
    J Pediatr; 1986 Jul; 109(1):131-4. PubMed ID: 3088240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of hyperammonemia in stuporous states induced by sodium valproate].
    Warter JM; Marescaux C; Rumbach L; Micheletti G; Chabrier G; Koehl C; Imler M; Collard M
    Rev Neurol (Paris); 1983; 139(12):753-7. PubMed ID: 6420866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperammonaemia: a possible mechanism for valproate encephalopathy.
    Coulter DL; Allen RJ
    Lancet; 1980 Jun; 1(8181):1310-1. PubMed ID: 6104123
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.